Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

Background: A fixed dose of 200 mg of pembrolizumab every 3 weeks (Q3W) is the standard of care for patients with stage IV non-small cell lung cancer (NSCLC) and PDL1 ≥50%. In April 2020, based on pharmacokinetic modeling without formal comparative studies, the FDA approved 400 mg every 6 weeks (Q6W...

Full description

Bibliographic Details
Published in:	Current Oncology
Main Authors:	Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Subjects:	PDL1 pembrolizumab dosing schedule NSCLC
Online Access:	https://www.mdpi.com/1718-7729/29/11/685

Similar Items

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
by: Rebekah Rittberg, et al.
Published: (2023-05-01)

Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC
by: David J. Cantor, MD, PhD, et al.
Published: (2024-06-01)

Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports
by: Fadi Nasr, et al.
Published: (2019-06-01)

Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
by: Yoko Tsukita, MD, PhD, et al.
Published: (2025-05-01)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022-01-01)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022-08-01)

FOCUS ON NIVOLUMAB IN NSCLC
by: Diego Luigi Cortinovis, et al.
Published: (2016-12-01)

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice
by: Magdalena Knetki-Wróblewska, et al.
Published: (2024-01-01)

BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report
by: Corazon A. Ngelangel, et al.
Published: (2024-09-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01)

Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC
by: Sun Min Lim, MD, PhD, et al.
Published: (2025-10-01)

Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report
by: Paola Maria Medusa, et al.
Published: (2022-11-01)

Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01)

Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer
by: Marina C. Garassino, et al.
Published: (2025-06-01)

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer
by: Alexandre Bertucci, et al.
Published: (2020-11-01)

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
by: Arjun Bhadhuri, et al.
Published: (2019-12-01)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
by: Zhang X, et al.
Published: (2023-09-01)

Compromise or not? A case report of successful treatment of pembrolizumab‐induced hepatitis in a patient with non‐small cell lung cancer with low‐dose methylprednisolone and bicyclol
by: Yan'e Liu, et al.
Published: (2020-07-01)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
by: Elizabeth Dudnik, et al.
Published: (2021-01-01)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
by: Rebekah Rittberg, et al.
Published: (2022-12-01)

Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma
by: Ka Hey Agnes Fong, et al.
Published: (2025-02-01)

Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on 18F-FDG-PET/CT
by: Karim Amrane, et al.
Published: (2022-12-01)

Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center
by: Evan Hall, et al.
Published: (2020-03-01)

Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
by: Ashley Jackson, BSc, et al.
Published: (2023-12-01)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
by: Joseph Mabbitt, et al.
Published: (2023-08-01)

Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis
by: Yanhao Liu, et al.
Published: (2024-03-01)

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia
by: Filip Marković, et al.
Published: (2025-05-01)

Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
by: Alfonso Fiorelli, et al.
Published: (2019-03-01)

SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis
by: Zhonghai Du, et al.
Published: (2021-05-01)

Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab
by: Maria Spiliotaki, et al.
Published: (2023-05-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
by: Alain Gelibter, et al.
Published: (2024-04-01)

Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients
by: Agnes Koch, et al.
Published: (2022-03-01)

Are offline ART decisions for NSCLC impacted by the type of dose calculation algorithm?
by: Dylan Callens, et al.
Published: (2024-03-01)

Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers
by: Chien-Hsiang Kao, et al.
Published: (2024-04-01)

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
by: Jonathan W. Riess, MD, MS, et al.
Published: (2025-06-01)

Oncolytic viral therapy with anti-PD-1 immunotherapy in a pediatric patient with diffuse intrinsic pontine glioma
by: M.P. Osuna Marco, M.D., et al.
Published: (2020-09-01)

Immunotherapy in nonsmall cell lung cancer (basket of choices)
by: Abhishek Raj
Published: (2020-01-01)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
by: Tao Li, et al.
Published: (2024-02-01)

Immune-mediated pneumonitis: A clinical conundrum in a patient with stage IV lung adenocarcinoma with a dramatic and durable response to checkpoint inhibitor case report
by: Ezra Bernstein, et al.
Published: (2022-12-01)